Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. 25 July 2019. Michael Mussallem.

Executive Summary

Edwards Lifesciences is giving up on its Centera transcatheter aortic valve replacement (TAVR) despite promising clinical results and will focus on its Sapien TAVR line. See what Michael Mussallem, Edwards's CEO, said about it here.

"Although we’re really pleased and excited about Centera, and there’s a number of clinicians who are as well, and that valve performed well, the way that valve delivers didn’t work as well in all anatomies as we would have liked. So it would’ve required us to make some enhancements to the delivery system." – Michael Mussallem, CEO, Edwards Lifesciences

Click here for a free trial of Medtech Insight

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts